Table 4. Molecular profile outcomes for all CUP patients.

Patient	Age at diagnosis (years)	No. of prior systemic therapies	Histology	No. of mutants	Specific mutations and aberrations identified
1	21.0	2	Epithelioid	1	EWSR1-ATF1 fusion
2	59.0	2	Squamous cell	6	PIK3CA H1047R	KDM6A S466*
					ALK L560F	CDC73 Q333*
					SOX2 amplification	CDK12 Q570*
3	17.9	2	Neuroendocrine	7	CCND1 amplification	FGF19 amplification
					MYCL1 amplification	FGF3 amplification
					MDM4 amplification	FGF4 amplification
					MLL2 R4904*
4	21.2	3	Neuroendocrine	0	N/A
5	33.8	1	Adenocarcinoma	8	FBXW7 splice 726+1 G>A	APIP-NOTCH1 fusion
					FGFR1 amplification	TP53 L45P, Q38fs*79
					ARID1A Y1211fs*5	MYST3 amplification
					ETV1 rearrangement
6	49.4	5	Squamous cell	0	N/A
7	70.2	8	Carcinoma	4	FBXW7 R465H	CCNE1 amplification
					PIK3CA Q75E	TP53 R273C
8	72.0	6	Carcinoma	2	FBXW7 W244*	TP53 R248Q
9	49.2	2	Carcinoma	8	PIK3CA E545K & amplification	FGFR1 amplification
						SOX2 amplification
					KRAS amplification	TP53 R196*
					CCND1 amplification	CDKN2A/B loss
10	44.0	3	Carcinoma	1	CTNNB1 S33P
11	72.4	3	Adenocarcinoma	2	SMARCB1 I365fs*22+	SETD2 G1644*, N2071fs*17
12	24.7	0	Sarcomatoid	1	EWSR1-CREB1 fusion
13	65.0	3	Epithelioid	2	EWSR1-NR4A3 fusion	ATRX R840fs*29
14	56.5	2	Squamous cell	7	BRCA2 W1692fs*3	ARID1A S1929fs*25
					CDKN2A/B loss	EMSY amplification
					MDM2 amplification	SMAD4 P130S
					SOX2 amplification
15	63.8	7	Adenocarcinoma	5	ERBB2 amplification	TP53 R248W
					CDKN2A/B loss	CREBBP S893L
					MCL1 amplification
16	71.7	8	Adenocarcinoma	3	FGFR3 R399C	NFE2L2 D11Y
					ARID1A E2250fs*28
17	48.0	1	Carcinoma	2	NF2 splice site 448-1G>A